Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need

被引：25
作者：
Bidell M.R. [1 ]
McLaughlin M. [2 ,3 ]
Faragon J. [4 ]
Morse C. [1 ]
Patel N. [1 ]
机构：
[1] Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, 12208, NY
[2] Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, 555 31st St, Downers Grove, Downers Grove, 60515, IL
[3] Department of Pharmacy, Northwestern Memorial Hospital, 251 E Huron St, Chicago, 60611, IL
[4] Division of HIV Medicine, Albany Medical College, 43 New Scotland Avenue, Albany, 12208, NY
来源：
Infectious Diseases and Therapy | 2016年 / 5卷 / 3期
关键词：
Effectiveness; Genotype; Hepatitis C; Pharmacotherapy; Response; Safety; Treatment;
D O I：
10.1007/s40121-016-0118-x
中图分类号：
学科分类号：
摘要：
There have been dramatic advancements in the treatment of chronic hepatitis C (HCV) infection. This is largely due to the approval of several direct-acting antiviral agents (DAAs) from a variety of medication classes with novel mechanisms of action. These therapies are a welcomed advancement given their improved efficacy and tolerability compared to pegylated interferon and ribavirin (RBV)-based regimens. These convenient, all-oral regimens treat a variety of genotypes and often offer high cure rates in a variety of HCV-infected populations. While there are several benefits associated with these therapies, there are also notable shortcomings. Shortcomings include diminished response or need for adjunctive RBV in difficult-to-treat populations (decompensated cirrhosis, active substance abuse patients, advanced kidney disease, etc.), activity against select genotypes, substantial drug–drug interaction potential, and high cost. Therefore, while current DAA-based therapies have several favorable attributes, each also has its limitations. The purpose of this review is to (1) identify the characteristics of an ideal HCV treatment regimen, (2) describe desirable features of existing regimens, (3) summarize limitations of existing regimens, and (4) introduce promising emerging therapies. This manuscript will serve as a guide for evaluating the caliber of future HCV treatment regimens. © 2016, The Author(s).
引用
收藏
页码：299 / 312
页数：13
相关论文
共 30 条
  • [1] Kohli A., Kapoor R., Sims Z., Et al., Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study, Lancet Infect Dis., 15, 9, pp. 1049-1054, (2015)
  • [2] Holmberg S.D., Spradling P.R., Moorman A.C., Denniston M.M., Hepatitis C in the United States, N Engl J Med, 368, 20, pp. 1859-1861, (2013)
  • [3] Lawitz E., Mangia A., Wyles D., Et al., Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 368, 20, pp. 1878-1887, (2013)
  • [4] Martinot-Peignoux M., Stern C., Maylin S., Et al., Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin, Hepatology, 51, 4, pp. 1122-1126, (2010)
  • [5] Yoshida E.M., Sulkowski M.S., Gane E.J., Et al., Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus, Hepatology, 61, 1, pp. 41-45, (2015)
  • [6] Aghemo A., Rumi M.G., Monico S., Et al., The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype, Antivir Ther., 14, 4, pp. 577-584, (2009)
  • [7] Di L., The role of drug metabolizing enzymes in clearance, Expert Opin Drug Metab Toxicol., 10, 3, pp. 379-393, (2014)
  • [8] Lawitz E., Sulkowski M.S., Ghalib R., Et al., Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study, Lancet, 384, 9956, pp. 1756-1765, (2014)
  • [9] Zahnd C., Salazar-Vizcaya L.P., Dufour J.F., Swiss H.I.V., Team H.C.C.S., Impact of deferring HCV treatment on liver-related events in HIV+ patients. Abstract 150. Conference on retroviruses and opportunistic infections, Seattle, February, pp. 23-24, (2015)
  • [10] Gritsenko D., Hughes G., Ledipasvir/sofosbuvir (harvoni): improving options for hepatitis C virus infection, P T., 40, 4, pp. 256-276, (2015)
123